LRRK2 and Parkinson disease: This LRRK2-G2019S-mutated PD organoid model was employed to screen a mutant-specific drug, an LRRK2-specific-inhibitor, which restored mitochondrial abnormalities and prevented the degeneration of dopaminergic neurons [20].